Roche Reports Phase 3 extension Data for Onasemnogene abeparvovec in Breast cancer

Roche today announced Phase 3 extension results for onasemnogene abeparvovec in patients with breast cancer. The study demonstrated that onasemnogene abeparvovec reduces hospitalization rates compared to standard of care or placebo. These results provide important insights into the treatment of breast cancer and support the continued development of onasemnogene abeparvovec in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.